Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMorell Daniel, Mariona
dc.contributor.authorCasanovas López, Enric Lluís
dc.contributor.authorPanesso Romero, Melissa
dc.contributor.authorBenitez Carabante, Maria Isabel
dc.contributor.authorUria Oficialdegui, Maria Luz
dc.contributor.authorAlonso, Laura
dc.contributor.authorDiaz de Heredia, Cristina
dc.date.accessioned2025-10-21T10:49:42Z
dc.date.available2025-10-21T10:49:42Z
dc.date.issued2025-07-24
dc.identifier.citationBenítez Carabante MI, Morell Daniel M, Uría Oficialdegui ML, Casanovas López E, Panesso Romero M, Alonso García L, et al. Autoimmune neutropenia: a rare complication of allogeneic hematopoietic stem cell transplantation? Front Immunol. 2025 Jul 24;16:1640546.
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/11351/13895
dc.descriptionChildren; Graft failure; Granulocyte antibodies
dc.description.abstractBackground: Autoimmune cytopenias (AIC) are rare complications of allogeneic hematopoietic stem cell transplantation (HSCT). Autoimmune neutropenia (AIN) is the least common type of AIC, and data on its incidence, risk factors and prognosis are scarce. This study aims to describe the incidence of AIN, its potential risk factors, and its clinical outcomes. Study design: This retrospective study included children who underwent a first allogeneic HSCT between 2015 and 2022. Patients with primary graft rejection were excluded. The primary endpoint was the incidence of AIN. Secondary endpoints included secondary graft failure (GF), overall survival (OS), and event-free survival (EFS). Results: A total of 208 patients were included, 30 of whom were diagnosed with AIN. The median time from HSCT to AIN diagnosis was 104 days, with a cumulative incidence of 8.73% (95%CI, 5.6-13.51) at 6 months and 14.74% (95%CI, 10.47-20.55) at 2 years after HSCT. No risk factors were found to be associated with AIN. The cumulative incidence of secondary GF at 2 years was 13.75% (95%CI, 5.38-32.68) in patients with AIN compared to 4.73% (95%CI, 2.39-9.25) in patients without AIN (p=0.06). There were no differences in terms of OS or EFS between patients with AIN and patients without AIN, with 3-year OS of 82.9% (95%CI, 63.6-92.5) vs 81.8% (95%CI, 75.26–86.77) (p=0.64) and 3-year EFS of 72.8% (95%CI, 52.8-85.4) vs 79% (95%CI, 72.2-84.31) (p=0.67). We identified two patients with specific human neutrophil alloantigen antibodies (anti-HNA), one of whom had a secondary graft failure. Conclusions: AIN may be a more frequent complication in post-HSCT pediatric patients than previously reported. Patients with AIN may be at a higher risk of secondary GF, but whether the risk of secondary GF is an important issue in patients with AIN needs to be explored in larger cohorts of patients. The study of specific anti-HNA in high-risk AIN patients should be considered.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Immunology;16
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectInfants
dc.subjectMalalties autoimmunitàries
dc.subjectNeutropènia - Diagnòstic
dc.subjectCèl·lules mare hematopoètiques - Trasplantació
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.mesh/adverse effects
dc.subject.meshChild
dc.subject.meshAutoimmune Diseases
dc.subject.meshNeutropenia
dc.subject.mesh/diagnosis
dc.titleAutoimmune neutropenia: a rare complication of allogeneic hematopoietic stem cell transplantation?
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fimmu.2025.1640546
dc.subject.decstrasplante de células madre hematopoyéticas
dc.subject.decs/efectos adversos
dc.subject.decsniño
dc.subject.decsenfermedades autoinmunes
dc.subject.decsneutropenia
dc.subject.decs/diagnóstico
dc.relation.publishversionhttps://doi.org/10.3389/fimmu.2025.1640546
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Benítez Carabante MI, Morell Daniel M, Uría Oficialdegui ML, Panesso Romero M, Alonso García L, Díaz-de-Heredia C] Servei d’Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Casanovas López E] Immunohaematology Laboratory, Banc de Sang i Teixits, Barcelona, Spain
dc.identifier.pmid40777012
dc.identifier.wos001545112500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record